Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Stocks Pressured by Rising Oil Prices and Bond Yields

View original at nasdaq.com
Stocks Pressured by Rising Oil Prices and Bond Yields The S&P 500 Index ($SPX) (SPY) today is down -0.26%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.80%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.16%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Most of American Eagle Outfitters' profit will be generated in the second half of the year

    80% confidence
  • Inflation is a bigger concern than economic growth as ECB assesses implications of war in Iran

    80% confidence
  • Astera Labs rated buy with $250 price target

    80% confidence
  • S&P earnings growth expected to climb by 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence
  • Real-time risk premium for crude oil at $18/barrel, corresponding to impact of six-week full halt to tanker traffic in Strait of Hormuz

    80% confidence
  • Prolonged conflict in Middle East would risk pushing inflation expectations higher

    80% confidence
  • Ships sailing through Strait of Hormuz could be at risk from missiles or rogue drones

    80% confidence
  • Excluding Magnificent Seven megacap tech stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
  • Four of six tanks at Saudi Arabia's Ras Tanura refinery were full, and Ju'aymah terminal is quickly running out of spare capacity

    80% confidence
  • Fastenal February daily sales rate estimate of 7.2%

    80% confidence
  • Broadcom expects its AI chip sales to top $100 billion next year

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com